Current stock page

Stock Analysis

AxoGen, Inc. (AXGN) Stock Analysis

AxoGen, Inc. (AXGN) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

AXGN Stock Analysis Summary

AxoGen, Inc. (AXGN) currently has an AIQ Score of 65/100, indicating a bullish setup. Momentum is the strongest factor at 82/100. Value is the weakest current factor at 33/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 18, 2026 · Market-close data

AXGN at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$56.95
AIQ Score65/100
Overall ViewBullish
Technical Analysis ConsensusStrong Buy
Market Cap$3.09B
P/E Ratio (TTM)-85.18
Forward P/E—
EPS (Q3 FY2026)$0.04
Revenue (Q3 FY2026)$75.83M
Dividend Yield (TTM)0.00%
Beta1.09
Volume2.11M
52-week range$23.00-$59.72
RSI 1469.94
50-Day SMA$43.27
200-Day SMA$40.53
Analyst Price Target$58.13
Next EarningsFeb 23, 2027
As of Nov 18, 2026 · Market close

AXGNAxoGen, Inc.

Healthcare / Medical - Devices

Absolute Strength

Above Peers

BullishEdge 7/10
$56.95+$1.58 (+2.85%)

Latest quote

  • Momentum
    82
  • Value
    33
  • Quality
    70
  • Risk resilience
    55
  • Sentiment
    —
algovestiq.comScore data as of Nov 18, 2026

AXGN Stock Analysis Summary

AxoGen, Inc. (AXGN) currently has an AIQ Score of 65/100, indicating a bullish setup. Momentum is the strongest factor at 82/100. Value is the weakest current factor at 33/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 18, 2026 · Market-close data
AIQ Composite Posture: Bullish

In a bullish regime, AXGN has AIQ Score of 65/100 with Momentum base of 82/100 and fading Value at 33/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (82/100) leads while Value (33/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 2.85% stock move · AXGN classified in Medical - Devices.

Current Evidence

BullishAXGN is in a bullish AIQ regime; Momentum is the strongest visible factor at 82/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is AXGN Bullish or Bearish Right Now?

AXGN currently has a bullish overall setup. Momentum is the strongest factor at 82/100, while Value is weakest at 33/100. The current evidence suggests a constructive setup.

Bull Case
  • - Quality is supportive at 70/100.
  • - Momentum is constructive at 82/100.
  • - Price is +29.27% above its 50-day SMA.
  • - Analyst target implies +2.06% upside from the latest quote.
  • - Technical consensus has more buy votes than sell votes (37 vs 5).
Bear Case
  • - Value is the current constraint at 33/100.

Current Consensus

AXGN's Technical Analysis Consensus is currently Strong Buy, with 37 buy, 4 neutral, and 5 sell votes. AXGN's 14-day RSI is 69.94, which places the stock in a constructive momentum range. AXGN's beta is 1.09, indicating market sensitivity broadly in line with the market.

Signal Confidence
High agreement

What Changed in AXGN?

The largest recent change in AXGN is Momentum moving up by 7.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+2.0
Momentum
+7.0
Quality
+0.0
Risk
+0.0

What Would Change the AXGN Outlook?

The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

AXGN Decision Framework

Public evidence layers, setup checks, and risk context for AxoGen, Inc..

AxoGen, Inc. (AXGN) Stock Analysis

AxoGen, Inc. has an AIQ Score of 65/100 in a Bullish regime. Momentum is strongest at 82/100. Beta is 1.09, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextAXGN is in a Bullish AIQ regime with score 65/100.
Signal ConflictThe primary conflict is that momentum leads at 82/100 while value lags at 33/100.
Factor EvidenceMomentum 82/100 · Value 33/100 · Quality 70/100 · Risk 55/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 82/100.

TimingPass

Momentum is 82/100 and RSI (14) is 69.9.

Regime fitPass

AXGN is in a Bullish regime at 65/100.

Risk controlWait

Risk factor is 55/100 with beta 1.09 and annual volatility 61.27%.

ConflictWait

Current conflict: momentum leads at 82/100 while value lags at 33/100.

AIQ Score
65/100
Price
$56.95
Beta
1.09
RSI (14)
69.9

AXGN Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

AXGN Fundamentals

AXGN valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$75.83M
Net income
$2.33M
Free cash flow
$15.14M
View full AXGN fundamental analysis

AXGN Technical Analysis

AXGN technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
69.94
Price vs SMA-50
+29.27%
View full AXGN technical analysis

AXGN Stock Catalysts

Track AXGN earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 23, 2027
Analyst target
$58.13
News items
4
View AXGN earnings and stock catalysts

AXGN Dividend Analysis

AXGN dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View AXGN dividend history and analysis

AXGN Financial Data

AXGN revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$75.83M
EPS
$0.04
Periods
8
View AXGN financials

AXGN Risk Analysis

AXGN volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.09
Risk score
55/100
1Y volatility
61.27%
View AXGN risk analysis

AXGN Stock News

AXGN stock news, market tone, recent headlines, and catalyst context.

News items
4
Updated
Nov 18, 2026
Sentiment
—
Read AXGN stock news

AXGN vs Medical - Devices Peers

Current peer cohort: AXGN · BBNX · BFLY · BIO · BRKR. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
AXGN
Current stock
65/10033/10082/10055/1001.6161.27%Current
BBNX
Beta Bionics, Inc.
54/10039/10072/10036/100-0.1684.66%AXGN vs BBNX
BFLY
Butterfly Network, Inc.
47/10029/10063/10032/1001.4121.33%AXGN vs BFLY
BIO
Bio-Rad Laboratories, Inc.
73/10080/10079/10074/1000.4736.18%AXGN vs BIO
BRKR
Bruker Corporation
64/10053/10083/10044/1000.8959.79%AXGN vs BRKR
Pairwise Compare links: BBNX · BFLY · BIO · BRKRAXGN vs BBNXAXGN vs BFLYAXGN vs BIOAXGN vs BRKRCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 18, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 18, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a AXGN stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for AXGN: historical return with reinvested dividends, dollar-cost averaging (DCA) backtest and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 19, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-85.18
As of Nov 18, 2026
Revenue growth
26.22%
Gross margin
74.18%
Current debt / equity
0.04
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$75.83M
Quarter net income
$2.33M
Quarter free cash flow
$15.14M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bullish
Momentum
Bullish
RSI 14
69.94
MACD
4

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
55/100
Beta
1.09
Annual volatility
61.27%
Max drawdown
-33.08%

AXGN Stock FAQ

What is AXGN stock price today?

AxoGen, Inc.'s current stock price is $56.95. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is AXGN bullish or bearish right now?

AXGN's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is AXGN's market cap?

AXGN's market cap is $3.09B based on the latest completed market-close snapshot from Nov 18, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is AXGN's current P/E ratio?

AXGN's current P/E ratio is -85.18 based on the latest completed market-close snapshot from Nov 18, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is AXGN's RSI?

AXGN's 14-day RSI is 69.94 based on the latest completed market-close snapshot from Nov 18, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is AXGN above its 50-day and 200-day moving averages?

AXGN is 29.27% from its 50-day SMA and 38.00% from its 200-day SMA based on the latest completed market-close snapshot from Nov 18, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is AXGN's next earnings date?

AXGN's next earnings date is currently listed as Feb 23, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does AXGN pay a dividend?

AXGN's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 18, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.